AbbVie’s Rinvoq notches Crohn’s disease win amid classwide JAK safety concerns
AbbVie's blockbuster hopeful Rinvoq notched a win in a tricky-to-treat group of Crohn's disease patients, potentially adding another arrow to the company's post-Humir...